| [June 20, 2017] |
 |
The BIO International Convention Starts Day Two with a David Cameron Keynote
The 2017 BIO International Convention (BIO 2017), the world's largest
gathering of the biotechnology industry, entered the second day of
compelling, immersive programming united under the theme of
"Breakthrough." Hosted by the Biotechnology Innovation Organization
(BIO), BIO 2017 will run through Thursday, June 22 at the San Diego
Convention Center.
A keynote session with David Cameron, Former Prime Minster of the United
Kingdom, leads BIO 2017's second day of programming, which will also
include several fireside chats and super sessions.
Tuesday, June 20 Highlights Include:
-
Keynote: David
Cameron, Former Prime Minister of the United Kingdom
David
Cameron, will be interviewed by BIO President & CEO, Jim Greenwood for
a worldly discussion on the rapidly changing political landscape both
in the United States and abroad. BIO will also recognize BioGENEius
student award winners and introduce BIO's new Board Chair, John
Maraganore, Ph.D.
9:00 - 10:30 a.m. | Ballroom 20, Upper Level
-
PLEASE NOTE: Keynotes are open to Convention Access and
Partnering Attendees. Seating is first-come, first-served.
-
Fireside Chat: David
Hung, MD, Chief Executive Officer, Axovant Sciences
Join
us for a fireside chat with David T. Hung, MD, Chief Executive Officer
at Axovant Sciences. Dr. Hung has served as the Chief Executive
Officer and as a member of the Board since April 2017.
11:00
a.m. - 12:00 p.m. | Room 6A, Upper Level
-
Super Session: Our
Common Goal: Ensuring Access and Affordability of Innovative Medicines
Join
us for a wide-ranging, lively conversation with healthcare industry
veterans as they debate and discuss the central question facing our
industry: How do we ensure access and affordability of innovative
medicines? The panelists will determine where there is common ground
and where the debate is heading in the coming years. The focus will be
on solutions, on finding areas of agreement and where fresh and
innovative thinking can move us past the roadblocks of past debates.
Get the panelists' unique insights and an unvarnished look at the most
pressing issues we face from leaders who have been on the frontlines
of healthcare innovation for decades.
12:15 - 1:30 p.m. |
Room 6A, Upper Level
-
Super Session: Dealmakers'
Intentions: 2017 Market Outlook
While the past year
has seen a fading in the IPO market, the volume of deal flow and
valuations for M&A remain high. Many of the largest industry members
have strong cash positions, and most analysts continue to expect
pipeline enhancement via acquisition. As political forecasts suggest
high potential for tax reform and other changes in how international
deals might be reviewed, there are multiple ways 2017 could be a great
year or a terrible year for biopharma M&A. This session will talk
through the likely and extreme scenarios, as well as provide insight
on what signs to watch for from Washington and Wall St. along the way.
Session attendees will hear updated findings from two unique,
forward-looking measures of deal-making in the industry: the inVentiv
Health Consulting Dealmakers' Intentions Study and the BIO One-on-One
Partnering Forecast. Based on a survey of more than 150 industry
executives and business development professionals, Dealmakers'
Intentions provides insight into what will likely drive the industry's
partnering and M&A efforts moving forward and the implications for
deal-making over the next year or more. Now in its ninth year,
analysis will include year-over-year trends, deal metrics and broader
M&A data. Additionally, a highly distinguished panel of deal-makers
will explore the impact these market forces will have on
pharmaceutical and biotech companies as they strive to make the next
big deal.
12:15 - 1:30 p.m. | Room 6B, Upper Level
Wednesday, June 21 Highlights Include:
-
Keynote: Ann
Romney, Wife of Mitt Romney, Patient Advocate and Best-Selling Author
Ann
Romney will take the stage to discuss her experience living with
Multiple Sclerosis and share personal stories of trials and
tribulations as a patient. With remarkable stories and insights that
will touch all audiences, her valued perspective on her life in and
out of the political spotlight is engaging and informative. BIO
President & CEO, Jim Greenwood, will also give his annual "State of
the Biotechnology Industry" address, discussing the latest challenges,
opportunities and breakthroughs facing the biotechnology industry.
9:00
- 10:30 a.m. | Ballroom 20, Upper Level
-
PLEASE NOTE: Keynotes are open to Convention Access and
Partnering Attendees. Seating is first-come, first-served
-
Fireside Chat: Francis
deSouza, President & CEO, Illumina
Join us for a
fireside chat with Francis deSouza, President & CEO of Illumina.
Francis deSouza was appointed President & CEO of Illumina in 2016 and
is responsible for directing all aspects of company strategy,
planning, and operations. He initially joined the company as President
in 2013, and led Illumina's business units and core functions
responsible for envisioning, developing and producing the company's
products.
11:00 a.m. - 12:00 p.m. | Room 5B, Upper Level
-
Super Session: The
Trade and Investment Policies of the Trump Administration
After
6 months in office, what is the outlook and implications for the
biotechnology industry for the Trump Administration's trade and
investment policies? This panel will focus on the North American Free
Trade Agreement (NAFTA), Europe/UK, China and other notable areas.
12:15
- 1:30 p.m. | Room 6A, Upper Level
-
Fireside Chat: Kathleen
"Kate" Rubins, PhD, Astronaut, NASA
Wednesday, June 21
Join
us for a fireside chat with Kate Rubins, NASA Astronaut. Kate was
selected by NASA in 2009 and completed her first spaceflight on
Expedition 48/49, where she became the first person to sequence DNA in
space. She spent 115 days in space and conducted two spacewalks.
1:45
- 2:45 p.m. | Room 5B, Upper Level
-
Fireside Chat: Understanding
the Patient Voice: Three Unique Perspectives on Healthcare
Wednesday,
June 21
The role of the patient has evolved dramatically
over the past decade. Not only are patients increasingly more involved
in their healthcare decision making, they are also passionate
advocates who work tirelessly to advance drug development research and
development and secure a public policy environment that is
patient-centric. Join a discussion with three patient advocates as
they discuss their journeys to diagnosis and their viewpoints on our
healthcare system. They will share their perspectives on what it means
to be a patient and how they are advocating in their own unique ways
to achieve a common goal: bringing new treatments to patients.
3:00
- 4:15 p.m. | Room 5B, Upper Level
-
Emerging Opportunities in Global Health: The
African Cancer Crisis
In 2015, the annual deaths in
Africa due to cancer surpassed those due to malaria. For many in the
developed world, cancer is a life-changing disease - but it is no
longer a death sentence. The same cannot be said for most cancer
patients in Africa. Cancer is a growing crisis on the African
continent. In the past two decades, cancer incidence in Africa has
doubled and deaths due to cancer have increased 62%. This is in stark
contrast to the United States, where cancer incidence has increased
60% but deaths have increased only 21%. This African cancer epidemic
is anything but straightforward, yet it must be prioritized. This
panel session will explore the current state of cancer in Africa and
describe how pharmaceutical and biotechnology companies can engage and
begin to tackle this crisis before it's too late. The panel will
describe Africa's cancer burden and the realities of cancer diagnosis
and treatment on the continent. The discussion will include the
perspective of government and industry in setting priorities,
strategies, and access to medicines. Finally, the panel will discuss a
new program launched by BIO Ventures for Global Health (BVGH) - the
African Access Initiative (AAI) - with the aim of improving cancer
patient management and creating new business models to ensure
affordable, sustainable access to essential cancer technologies and
therapeutics in Africa.
3:00 - 4:30 p.m. | Room 27AB, Upper
Level
Follow the 2017 Convention @BIOConvention,
and join the conversation and @IAmBIOtech.
Media registration is open on Monday from 7:00 a.m. - 5:00 p.m. and on
Tuesday from 6:30 a.m. - 3:00 p.m. at the San Diego Convention Center.
The majority of attendees, 70 percent, are c-level executives. They
split evenly from large companies of 500 or more employees and small
companies of 50 employees or less.
The BIO International Convention is the largest global event for the
biotechnology industry and attracts the biggest names in biotech, offers
key networking and partnering opportunities, and provides insights and
inspiration on major trends affecting the industry. The Convention will
highlight the latest trends and the newest opportunities for executives,
investors, scientists, policy leaders, and media from around the world.
Speakers at the sessions will share breakthroughs in medicine,
diagnostics, the environment, energy production, business operations,
financing, partnerships, policy issues and food and agriculture. Visit http://convention.bio.org/
for the most up-to-date program and speaker information.
About BIO
BIO is the world's largest trade association
representing biotechnology companies, academic institutions, state
biotechnology centers and related organizations across the United States
and in more than 30 other nations. BIO members are involved in the
research and development of innovative healthcare, agricultural,
industrial and environmental biotechnology products. BIO also produces
the BIO
International Convention, the world's largest gathering of the
biotechnology industry, along with industry-leading investor and
partnering meetings held around the world. BIOtechNOW is
BIO's blog chronicling "innovations transforming our world" and the BIO
Newsletter is the organization's bi-weekly email newsletter. Subscribe
to the BIO Newsletter.
Upcoming BIO Events
BIO World Congress
on Industrial Biotechnology
Montréal,
Canada
July 23-26, 2017
BIO Patient and Health
Advocacy Summit
The
Mayflower Hotel, Washington, DC
October 2-3, 2017
BIO Investor Forum
San Francisco
October 17-18, 2017
View source version on businesswire.com: http://www.businesswire.com/news/home/20170620005738/en/
[ Back To TMCnet.com's Homepage ]
|
